February, 1 2022 SmartDyeLivery secures additional seven-figure funding

Financ­ing round reflects con­fi­dence in poten­tial of inno­v­a­tive nanotherapies

Using nanopar­ti­cles to trans­port active ingre­di­ents to dis­eased organs — with this con­cept and the lat­est pre­clin­i­cal study results, Smart­Dye­Liv­ery GmbH con­vinced its investors to invest a seven-fig­ure sum in this fund­ing round. The lead investor, bm‑t beteili­gungs­man­age­ment thürin­gen gmbh (bm|t), as well as a pri­vate investor from the exist­ing con­sor­tium invested in order to enable the fur­ther growth of the inno­v­a­tive com­pany from Jena.

“We are delighted with the devel­op­ment results achieved and are very grate­ful for the con­tin­ued trust of our investors — espe­cially in the cur­rent envi­ron­ment with unfore­seen global chal­lenges,” explains CEO Dr. Marc Lehmann. “The lat­est results from the non-clin­i­cal reg­is­tra­tion stud­ies make it clear that the com­pany is on the right track with the first appli­ca­tion of the plat­form tech­nol­ogy for sep­tic liver fail­ure,” said Ste­fan Jahn, Senior Invest­ment Man­ager at bm|t. The new cap­i­tal will be used to pre­pare and exe­cute the first-in-man study.

About SmartDyeLivery

Smart­Dye­Liv­ery GmbH, based in Jena, Ger­many, is devel­op­ing a uni­ver­sal plat­form tech­nol­ogy based on func­tion­al­ized nanopar­ti­cles that can be used to trans­port drugs or other car­goes to the desired organ in a tar­geted man­ner. The company´s aim is to pro­vide new ther­a­peu­tic options for dis­eases that were pre­vi­ously untreat­able or dif­fi­cult to treat. The inno­v­a­tive, pro­pri­etary tech­nol­ogy can also be used for diag­nos­tic or ther­a­nos­tic appli­ca­tions. For more infor­ma­tion, please visit www.smartdyelivery.de/en

About bm|t

bm t beteili­gungs­man­age­ment thürin­gen gmbh (bm|t), head­quar­tered in Erfurt, is the first address for ven­ture cap­i­tal invest­ments in Thürin­gen, Ger­many. bm|t cur­rently man­ages nine invest­ment funds with a total vol­ume of EUR 350 mil­lion and invests in inno­v­a­tive com­pa­nies with strong growth poten­tial across all indus­tries and all phases of the com­pany life cycle. More infor­ma­tion about bm|t is avail­able at www.bm‑t.com